ArticleCritical care (London, England)2026
Technical feasibility of hyperbaric oxygen therapy for gas embolism with ECMO support: a brief report.
Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGas embolism (GE) occurs when gas enters into the circulation. Whilst small quantities of gas may be harmless, massive, or systemic GE may be life-threatening, when associated with coma, cardiogenic shock, or cardiac arrest. GE is a known complication of Extracorporeal Membrane Oxygenation (ECMO). Hyperbaric Oxygen Therapy (HBOT) is a corner-stone of GE management. Delivery of HBOT in patients supported by ECMO is an emerging area of interest.
methodsWe aimed to assess the feasibility of using the Rotaflow I® (Maquet, Germany) ECMO device during HBOT, configured with mock circulatory loops (MCL) such that the pump head unit and oxygenator were located inside and the console external to the hyperbaric chamber. A control MCL was positioned outside the hyperbaric chamber with similar characteristics and parameters. Both oxygenators were alimented with oxygen sweep gas. Outflow stability was measured before, during and after a pressurization profile. Laboratory markers for hemolysis were assessed. Measurements were performed simultaneously on both MCL.
resultsECMO outflow displayed on the console remained stable during hyperbaric pressurization profile. [maximum variation (delta max) of 0.16 L/min (3.1%) during HBOT versus 0.19 L/min (3.8%) at atmospheric pressure]. No significant variation was found between pre- and post-oxygenator pressure in the H-ECMO device (delta max 1 mmHg in pre- and post-oxygenator). Hemoglobin, haptoglobin and schistocytes concentrations remained stable. Conversely, measured plasma-free hemoglobin and LDH were increased temporarily during run in the device exposed to HBOT, then decreased when back at atmospheric pressure. These changes are likely related to technical issues. No relevant changes were observed in the control.
conclusionDelivery of HBOT to patients with GE supported by ECMO seems technically feasible using a Rotaflow I® device with externalization of the console outside the hyperbaric chamber. No significant effect on performance or sustained effect on hemolysis were observed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.